APA (7th ed.) Citation

Melero, I., Lakhani, N., Powderly, J., Adjei, A., Lopez, J., Paz-Ares, L., . . . De Mattos-Arruda, L. (2024). 1072TiP Phase I/II dose escalation/expansion trial to evaluate safety and preliminary efficacy of DuoBody-EpCAM×4-1BB (BNT314/GEN1059) alone or in combination with an immune checkpoint inhibitor in patients with malignant solid tumors. Annals of Oncology, 35, S709. https://doi.org/10.1016/j.annonc.2024.08.1130

Chicago Style (17th ed.) Citation

Melero, I., et al. "1072TiP Phase I/II Dose Escalation/expansion Trial to Evaluate Safety and Preliminary Efficacy of DuoBody-EpCAM×4-1BB (BNT314/GEN1059) Alone or in Combination with an Immune Checkpoint Inhibitor in Patients with Malignant Solid Tumors." Annals of Oncology 35 (2024): S709. https://doi.org/10.1016/j.annonc.2024.08.1130.

MLA (9th ed.) Citation

Melero, I., et al. "1072TiP Phase I/II Dose Escalation/expansion Trial to Evaluate Safety and Preliminary Efficacy of DuoBody-EpCAM×4-1BB (BNT314/GEN1059) Alone or in Combination with an Immune Checkpoint Inhibitor in Patients with Malignant Solid Tumors." Annals of Oncology, vol. 35, 2024, p. S709, https://doi.org/10.1016/j.annonc.2024.08.1130.